theranostics
Telix Seeks Approval of PET Imaging Agent Pixclara to Track Brain Cancer Treatment
Pixclara has potential as a companion diagnostic for Telix's LAT1-targeted radiopharmaceutical agent TLX101 in glioblastoma.
FDA Allowing Compassionate Use Access to Telix's Glioma PET Imaging Agent
Telix will seek FDA approval to sell TLX101-CDx as an imaging agent for advanced glioma patients.
Telix Files for FDA Approval for New PSMA-PET Imaging Agent TLX007-CDx
The firm already markets a radiopharmaceutical companion diagnostic for Pluvicto but is hoping to improve patient access with this new imaging agent.
Nuclidium, Guerbet Ink Deal to Develop Targeted Copper-Based Radiopharmaceuticals
The Swiss and French firms are teaming up to advance Nuclidium's pipeline of targeted radiopharmaceuticals using copper isotopes.
Oncodesign Precision Medicine, Navigo Proteins Partner to Develop Radiotheranostics
The firms aim to take advantage of synergies in their respective technologies to develop cancer radiotheranostics.